Chiedzo Mpofu

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Alba A. Brandes, Miguel Gil‐Gil, Frank Saran, Alain Carpentier et autres

it, es, gb, fr, au, ca, gr, ro, ch, at (code pays fourni par la source)

ACTR-78. TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA

Alba A. Brandes, Miquel Gil, Frank Saran, Alain Carpentier et autres

es, gb, fr, au, ca, it, gr, ro, ch (code pays fourni par la source)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study

Paul Emery, J.E. Gottenberg, Andrea Rubbert‐Roth, Piercarlo Sarzi‐Puttini et autres

gb, fr, de, it, ca, es, mx, us, ch (code pays fourni par la source)

FRI0248 Long-term efficacy and safety of tocilizumab (TCZ) monotherapy in patients (PTS) with rheumatoid arthritis (RA) previously methotrexate (MTX) naive or mtx free for 6 months prior to study start

Graeme Jones, Anthony Sebba, A. Anisfeld, Jenny Devenport et autres

au, us, ch, gb (code pays fourni par la source)

Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility

Puja Mehta, Sue Holder, BA Fisher, Tonia L. Vincent et autres

gb, fr, us, it, hu, au, de, be (code pays fourni par la source)

FRI0179 Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents

A. J. Ostor, Jose Andrés Román Ivorra, J. Wollenhaupt, Chiedzo Mpofu et autres

de, ch, fr, ca (code pays fourni par la source)

FRI0200 Relative effectiveness of rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis and an inadequate response to a single previous TNF inhibitor: Results from switch-RA, a global, comparative-effectiveness, observational study

Paul Emery, J.-E. Gottenberg, Piercarlo Sarzi‐Puttini, Robert J. Moots et autres

gb, it, ca, ch, mx (code pays fourni par la source)

AB0541 Factors associated with selection of rituximab vs alternative TNF inhibitor (TNFI) following TNFI failure in patients with rheumatoid arthritis: Sub-analysis of switch-RA, a global, comparative effectiveness observational study

J.-E. Gottenberg, Chiedzo Mpofu, W. Bensen, Andrea Rubbert‐Roth et autres

ch, ca, de, mx, es, it, gb (code pays fourni par la source)

Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn’s Disease

Chiedzo Mpofu, Barry J. Campbell, Sreedhar Subramanian, S Marshall-Clarke et autres

gb (code pays fourni par la source)

BASIC-ALIMENTARY TRACT Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn's Disease

Chiedzo Mpofu, Barry J. Campbell, Sreedhar Subramanian, C. Anthony Hart et autres

Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease

Paul Collins, Chiedzo Mpofu, Alastair J.M. Watson, Jonathan M. Rhodes

gb (code pays fourni par la source)

Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer 1 1The authors thank Professor T. K. Korhonen (Division of General Microbiology, University of Helsinki, Finland), who kindly donated Escherichia coli IH11165; Professor J.-F. Colombel (Laboratoire de Recherche sur les Maladies Inflammatoire de l’Intestine, Centre Hospitalier Universitaire, Lille, France) and Professor A. Darfeuille-Michaud (Faculte de Pharmacie, Clermont-Ferrand, France), who kindly donated the Crohn’s disease ileal isolates LF10 and LF82; and Dr. Keith Leiper (Gastroenterology Unit, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UK) for his cooperation in obtaining colorectal tissue specimens.As a consequence of the work described herein, a patent application has been filed by the University of Liverpool regarding the use of soluble plantain fiber in Crohn’s disease.

Helen Martin, Barry J. Campbell, C. Anthony Hart, Chiedzo Mpofu et autres

gb (code pays fourni par la source)